




**Massachusetts Institute of Technology
Harvard Medical School
Brigham and Women's Hospital
VA Boston Healthcare System**




2.79J/3.96J/20.441/HST522J

**UNIT CELL PROCESSES UNDERLYING
TISSUE ENGINEERING AND
REGENERATIVE MEDICINE**

M. Spector, Ph.D.

TISSUE ENGINEERING/ REGENERATIVE MEDICINE



TISSUE ENGINEERING

What is tissue engineering?

- Production of tissue *in vitro* by growing cells in porous, absorbable scaffolds (matrices).

Why is tissue engineering necessary?

- Most tissues cannot regenerate when injured or diseased.
- Even tissues that can regenerate spontaneously may not completely do so in large defects (*e.g.*, bone).
- Replacement of tissue with permanent implants is greatly limited.

TISSUE ENGINEERING

Problems with Tissue Engineering

- Most tissues cannot yet be produced by tissue engineering (*i.e., in vitro*).
- Implantation of tissues produced *in vitro* may not remodel *in vivo* and may not become integrated with (bonded to) host tissue in the body.

Solution

- Use of implants to facilitate formation (regeneration) of tissue *in vivo*.
 - “Regenerative Medicine”
 - Scaffold-based regenerative medicine

TISSUE ENGINEERING VS. REGENERATIVE MEDICINE*

TISSUE ENGINEERING

Regeneration *In Vitro*

Produce the fully formed tissue *in vitro* by seeding cells into a biomaterial matrix, and then implant the regenerated tissue into the body.

REGENERATIVE MED.

Regeneration *In Vivo*

Implant the biomaterial matrix with, or without seeded cells, into the body to facilitate regeneration of the tissue *in vivo*.

TISSUE ENGINEERING VS. REGENERATIVE MEDICINE

TISSUE ENGINEERING

Regeneration *In Vitro*

Advantages

- Evaluation of tissue prior to implantation

Disadvantages

- For incorporation, must be remodeling
- Stress-induced architecture cannot yet be produced *in vitro*

REGENERATIVE MED.

Regeneration *In Vivo*

Advantages

- Incorporation and formation under the influence of endogenous regulators (including mechanical strains)

Disadvantages

- Dislodgment and degrad. by mech. stresses *in vivo*

TISSUE ENGINEERING

Current Status

- No one has yet employed Tissue Engineering methods to fully regenerate any tissue that does not have the capability for spontaneous regeneration*.
 - The Integra skin has no hair or glandular structures and its architecture is close to but not identical to normal dermis.
 - The Carticel cartilage is not articular cartilage.
- Experience has taught us that full regeneration may not be necessary to achieve a meaningful clinical result (*e.g.*, pain relief, recovery of function, esthetics)
- How close to regeneration is good enough?

* Many examples of bone regeneration

TISSUE ENGINEERING ENDPOINTS

- **Morphological/Histological/Biochemical**
 - Match the composition and architecture of the tissue.
 - Problem: A complete analysis is difficult and no clear relationships yet with functional and clinical endpoints.
- **Functional**
 - Achieve certain functions; display certain properties (*e.g.*, mechanical properties).
 - Problem: Difficult to measure all properties; Which properties are the most important?
- **Clinical**
 - Pain relief.
 - Problems: Can only be evaluated in human subjects and the mechanisms (including the placebo effect) and kinetics of pain relief (*e.g.*, how long it will last) are unknown.

ELEMENTS* OF TISSUE ENGINEERING/ REGENERATIVE MEDICINE

- **MATRIX (SCAFFOLD)**
 - Porous, absorbable synthetic (*e.g.*, polyglycolic acid) and natural (*e.g.*, collagen) biomaterials
- **CELLS (Autologous or Allogeneic)**
 - Differentiated cells of same type as tissue
 - Stem cells (*e.g.*, bone marrow-derived)
 - Other cell types (*e.g.*, dermal cells)
- **REGULATORS**
 - Growth factors or their genes
 - Mechanical loading
 - Static versus dynamic culture (“bioreactor”)

* Used individually or in combination, but often with a scaffold)

TECHNOLOGY TOOL BOX

TISSUE ENGR./REGENERATIVE MED.

- **SCAFFOLD (MATRIX)**
 - Porous, absorbable biomaterial; can serve to regulate cell function prior to its absorption
- **CELLS**
- **REGULATORS**
 - Cytokines (growth factors)
 - Genes for growth factors
 - Antagonists of inhibitors
 - Fluid flow
 - Mechanical loading
 - Hydrostatic pressure
 - Shock wave and ultrasound
 - Electromagnetic radiation and magnetic fields


CELL THERAPY FOR LOCAL REPAIR*

Injection of Exogenous Cells; Cells Expanded in Number in Monolayer Culture

- Chondrocytes for cartilage repair (FDA-approved)
- Intervertebral disc cells for herniated disc (human trial)
- Myoblasts and stem cells for myocardial infarction (human trial)
- Cells injected into the brain (human)
- Stem cells into spinal cord lesions (animal)
- Cells into the retina (animal)

* An alternative strategy is to implant a scaffold seeded with the cells

**Arthroscopic
Debridement**



**“Micro-
fracture”**



**Osteochondral
Plug Autograft
 (“Mosaicplasty”)**

Figure by MIT OpenCourseWare.

30 years



Current Clinical Practice





**Total Knee
Replacement**




**Autologous chondrocytes
injected under a periosteal
flap (Genzyme; “Carticel”)**

Medical illustrations removed due to copyright restrictions.


Articular Cartilage



Extracellular Matrix



4 mm



Cell

10 μm

Figure by MIT OpenCourseWare.

Autologous Chondrocyte Implantation

Problems with the periosteum?



Image removed due to copyright restrictions.

Figure 1 in Brittberg, M., et al. "Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation." *NEJM* 331, no. 14 (1994): 889-895.
<http://content.nejm.org/cgi/content/abstract/331/14/889>

**This process has been commercialized
by Genzyme (for \$20,000).**

M Brittberg, *et al.*, *NEJM* 33:889 (1994)

Collagen membrane to replace a periosteal tissue graft to contain injected autologous chondrocytes (grown in culture)

Debridement

Images removed due to copyright restrictions.

Implantation of a collagen membrane to contain injected autologous chondrocytes

Future Clinical Practice Implementing Tissue Engineering





Figure by MIT OpenCourseWare.

Implantation of a **cell-seeded matrix**



“Microfracture”:
Stem cells from bone
marrow infiltrate the defect

Implantation of the **matrix alone**,
(or supplemented with growth
factors or genes for the GFs)

CELLS FOR TISSUE ENGINEERING/REGENERATIVE MEDICINE

- **Autologous (from same individual)**
 - Differentiated cells of same or other tissue type
 - Stem cells (adult)
- **Allogeneic (from another individual)**
 - Same as above
 - Fetal stem cells
 - Embryonic stem cells

TISSUE ENGINEERING

Issues to be Addressed

- Should the tissue be produced *in vitro*, for subsequent implantation, or *in vivo*?
- What scaffold should be used?
 - Material of fabrication, pore characteristics, absorbability, mechanical properties?
 - How to be manufactured?
- What cells are to be used?
 - Source of cells?
 - Under what conditions can cells be expanded in number *in vitro* while retaining their phenotype?
- What regulators are required to stimulate cell proliferation and matrix synthesis or to facilitate differentiation of stem cells?

Which Tissues Can Regenerate Spontaneously?

	Yes	No
Connective Tissues		
• Bone	✓	
• Articular Cartilage, Ligament, Intervertebral Disc, Others		✓
Epithelia (e.g., epidermis)	✓	
Muscle		
• Cardiac, Skeletal		✓
• Smooth	✓	
Nerve		✓

FACTORS THAT CAN PREVENT REGENERATION

- **Size of defect**
 - *e.g.*, bone does not regenerate in large defects
- **Collapse of surrounding tissue into the defect**
 - *e.g.*, periodontal defects
- **Excessive strains in the reparative tissue**
 - *e.g.*, unstable fractures

UNIT CELL PROCESSES FOR TISSUE REGENERATION

Regulator



UCP

Cell + Matrix \longrightarrow Product + Regulator

Connective
Tissue
Epithelia
Muscle
Nerve

Integrin

ECM
Adhesion
Protein
Collagen
Biomaterial

Mitosis
Synthesis
Migration
Contraction
Endocytosis
Exocytosis



CELL-MATRIX INTERACTIONS REQUIRED FOR TISSUE ENGINEERING

Connective Tissues (Musculoskeletal)	Mitosis ¹	Migration ²	Synthesis ³	Contract. ⁴
Bone	+	+	+	+
Articular Cartilage	-	-	-	+
Ligament/Tendon	+	-/+	?	+
Intervertebral Disc	?	?	?	+
Meniscus	-/+	?	?	+

¹ Inadequate mitosis requires exogenous **cells**.

² Inadequate migration may require a **scaffold** (*viz.*, when no clot).

³ Inadequate biosynthesis require **growth factors** or their **genes**.

⁴ Contraction ?

ELEMENTS OF TISSUE ENGINEERING/ REGENERATIVE MEDICINE

- **MATRIX (SCAFFOLD)**
 - Porous, absorbable synthetic (*e.g.*, polyglycolic acid) and natural (*e.g.*, collagen) biomaterials
- **CELLS (Autologous or Allogeneic)**
 - Differentiated cells of same type as tissue
 - Stem cells (*e.g.*, bone marrow-derived)
 - Other cell types (*e.g.*, dermal cells)
- **REGULATORS**
 - Growth factors or their genes
 - Mechanical loading
 - Static versus dynamic culture (“bioreactor”)

* Used individually or in combination, but often with a scaffold)

ROLES OF THE BIOMATERIALS/ SCAFFOLDS

- 1) the scaffold serves as a framework to support cell migration into the defect from surrounding tissues; especially important when a fibrin clot is absent.
- 2) serves as a delivery vehicle for exogenous cells, growth factors, and genes.
- 3) before it is absorbed a scaffold can serve as a matrix for cell adhesion to facilitate/“regulate” certain unit cell processes (e.g., mitosis, synthesis, migration) of cells *in vivo* or for cells seeded *in vitro*.
 - a) the biomaterial may have ligands for cell receptors (integrins)
 - b) the biomaterial may selectively adsorb adhesion proteins to which cells can bind
- 4) may structurally reinforce the defect to maintain the shape of the defect and prevent distortion of surrounding tissue.
- 5) serves as a barrier to prevent the infiltration of surrounding tissue that may impede the process of regeneration.

MIT OpenCourseWare
<http://ocw.mit.edu>

20.441J / 2.79J / 3.96J / HST.522J Biomaterials-Tissue Interactions
Fall 2009

For information about citing these materials or our Terms of Use, visit: <http://ocw.mit.edu/terms>.